Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Arrowhead Pharmaceuticals, Inc. (ARWR)
since 2013 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Arrowhead Pharmaceuticals, Inc..
Table 2 shows the detailed insider transactions.
This company's CIK number is 879407.
Total stock buying since 2013: $325,975.
Total stock sales since 2013: $183,121,190.
Total stock option exercises since 2013: $12,425,864.
Table 3. Detailed insider trading at Arrowhead Pharmaceuticals, Inc. (ARWR)
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2025-09-02 | Hamilton James C (Chief Medical Officer) | Sale | 15,000 | 25.00 | 375,000 |
| 2025-08-15 | Hamilton James C (Chief Medical Officer) | Sale | 9,389 | 20.00 | 187,780 |
| 2025-08-13 | Hamilton James C (Chief Medical Officer) | Sale | 611 | 20.00 | 12,220 |
| 2025-04-11 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 50,800 | 11.49 | 583,692 |
| 2025-04-10 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 50,000 | 10.87 | 543,500 |
| 2025-04-09 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 40,322 | 10.81 | 436,001 |
| 2025-03-13 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 51,425 | 15.07 | 774,974 |
| 2025-03-04 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 133,333 | 17.02 | 2,269,327 |
| 2025-03-04 | Anzalone Christopher Richard (Chief Executive Officer) | Option Ex | 133,333 | 7.75 | 1,033,330 |
| 2025-03-03 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 166,667 | 18.03 | 3,005,006 |
| 2025-03-03 | Anzalone Christopher Richard (Chief Executive Officer) | Option Ex | 166,667 | 7.75 | 1,291,669 |
| 2025-01-23 | Olukotun Adeoye Y (Director) | Sale | 959 | 21.00 | 20,139 |
| 2025-01-07 | O'brien Patrick (COO and General Counsel) | Sale | 8,000 | 19.69 | 157,520 |
| 2025-01-07 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 18,000 | 19.70 | 354,510 |
| 2025-01-06 | Hamilton James C (Chief Discovery/Trans Medicine) | Sale | 32,729 | 19.89 | 651,143 |
| 2025-01-06 | O'brien Patrick (COO and General Counsel) | Sale | 29,184 | 19.89 | 580,615 |
| 2025-01-06 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 27,167 | 19.89 | 540,351 |
| 2025-01-02 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 11,520 | 19.05 | 219,456 |
| 2024-12-18 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 26,712 | 21.46 | 573,239 |
| 2024-12-17 | Waddill William D. (Director) | Sale | 3,747 | 22.04 | 82,583 |
| 2024-12-17 | Given Douglas B (Director) | Sale | 547 | 22.04 | 12,055 |
| 2024-12-16 | Vakiener Victoria (Director) | Sale | 8,994 | 21.91 | 197,058 |
| 2024-12-16 | Waddill William D. (Director) | Sale | 3,748 | 21.90 | 82,081 |
| 2024-12-16 | Given Douglas B (Director) | Sale | 5,000 | 21.90 | 109,500 |
| 2024-07-02 | Oliver Tracie (Chief Commercial Officer) | Sale | 9,394 | 25.28 | 237,480 |
| 2024-05-02 | Vakiener Victoria (Director) | Sale | 1,799 | 23.31 | 41,934 |
| 2024-04-01 | Hamilton James C (Chief Discovery/Trans Medicine) | Sale | 6,000 | 28.03 | 168,180 |
| 2024-03-20 | Lu Hongbo (Director) | Buy | 1,000 | 27.50 | 27,500 |
| 2024-03-19 | Lu Hongbo (Director) | Buy | 1,000 | 28.00 | 28,000 |
| 2024-03-18 | Lu Hongbo (Director) | Buy | 1,000 | 27.49 | 27,490 |
| 2024-03-06 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 40,000 | 35.19 | 1,407,600 |
| 2024-01-12 | Hamilton James C (Chief Discovery/Trans Medicine) | Sale | 7,940 | 36.92 | 293,144 |
| 2024-01-11 | Vakiener Victoria (Director) | Sale | 4,720 | 38.35 | 181,035 |
| 2024-01-11 | Waddill William D. (Director) | Sale | 3,934 | 38.20 | 150,278 |
| 2024-01-11 | Ferrari Mauro (Director) | Sale | 3,147 | 38.22 | 120,262 |
| 2024-01-11 | Given Douglas B (Director) | Sale | 2,911 | 38.16 | 111,069 |
| 2024-01-05 | Oliver Tracie (Chief Commercial Officer) | Sale | 74 | 33.89 | 2,507 |
| 2024-01-05 | Hamilton James C (Other) | Sale | 32,143 | 34.90 | 1,121,726 |
| 2024-01-05 | San Martin Javier (Chief Medical Officer) | Sale | 8,303 | 34.93 | 289,998 |
| 2024-01-05 | O'brien Patrick (COO and General Counsel) | Sale | 22,841 | 34.88 | 796,625 |
| 2024-01-05 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 16,104 | 34.89 | 561,820 |
| 2024-01-04 | O'brien Patrick (COO and General Counsel) | Sale | 1,600 | 32.63 | 52,208 |
| 2024-01-03 | Hamilton James C (Other) | Sale | 6,300 | 32.54 | 205,020 |
| 2024-01-03 | O'brien Patrick (COO and General Counsel) | Sale | 8,749 | 32.60 | 285,243 |
| 2023-12-20 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 12,000 | 28.54 | 342,480 |
| 2023-11-20 | San Martin Javier (Chief Medical Officer) | Sale | 19,700 | 28.86 | 568,640 |
| 2023-10-25 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 24,338 | 24.21 | 589,222 |
| 2023-09-28 | Vakiener Victoria (Director) | Sale | 1,550 | 26.33 | 40,811 |
| 2023-09-18 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 57,755 | 28.14 | 1,624,936 |
| 2023-09-18 | Anzalone Christopher Richard (Chief Executive Officer) | Option Ex | 57,755 | 4.75 | 274,336 |
| 2023-07-03 | Oliver Tracie (Chief Commercial Officer) | Sale | 8,925 | 35.31 | 315,141 |
| 2023-06-30 | Hamilton James C (Other) | Sale | 3,000 | 35.53 | 106,590 |
| 2023-06-27 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 15,000 | 36.20 | 543,000 |
| 2023-05-05 | Given Douglas B | Sale | 6,500 | 40.90 | 265,850 |
| 2023-05-04 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 50,000 | 39.49 | 1,974,749 |
| 2023-05-04 | Anzalone Christopher Richard (Chief Executive Officer) | Option Ex | 50,000 | 2.01 | 100,499 |
| 2023-05-03 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 54,928 | 39.14 | 2,149,881 |
| 2023-05-03 | Anzalone Christopher Richard (Chief Executive Officer) | Option Ex | 54,928 | 2.01 | 110,405 |
| 2023-03-03 | Olukotun Adeoye Y (Director) | Sale | 11,350 | 32.65 | 370,577 |
| 2023-02-27 | Given Douglas B (Director) | Sale | 875 | 32.62 | 28,542 |
| 2023-01-09 | Waddill William D. (Director) | Sale | 3,200 | 30.00 | 96,000 |
| 2023-01-05 | O'brien Patrick (COO and General Counsel) | Sale | 15,000 | 37.39 | 560,850 |
| 2023-01-03 | Hamilton James C (Other) | Sale | 20,676 | 39.05 | 807,294 |
| 2023-01-03 | O'brien Patrick (COO and General Counsel) | Sale | 35,000 | 39.11 | 1,368,710 |
| 2022-12-29 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 30,625 | 40.00 | 1,225,000 |
| 2022-12-21 | O'brien Patrick (General Counsel) | Option Ex | 32,000 | 6.15 | 196,800 |
| 2022-11-21 | San Martin Javier (Chief Medical Officer) | Sale | 19,500 | 30.30 | 590,850 |
| 2022-09-27 | Anzalone Christopher Richard (Chief Executive Officer) | Option Ex | 40,624 | 30.99 | 1,258,937 |
| 2022-07-07 | Anzalone Christopher Richard (Chief Executive Officer) | Option Ex | 2,501 | 14.54 | 36,364 |
| 2022-02-11 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 146,388 | 51.70 | 7,568,259 |
| 2022-02-11 | Anzalone Christopher Richard (Chief Executive Officer) | Option Ex | 146,388 | 5.19 | 759,753 |
| 2022-01-07 | Anzalone Christopher Richard (Chief Executive Officer) | Option Ex | 11,806 | 5.19 | 61,273 |
| 2022-01-05 | Hamilton James C (Other) | Sale | 6,250 | 62.60 | 391,275 |
| 2022-01-05 | O'brien Patrick (General Counsel) | Sale | 32,500 | 62.59 | 2,034,240 |
| 2022-01-05 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 40,000 | 62.41 | 2,496,200 |
| 2022-01-04 | Hamilton James C (Other) | Sale | 19,375 | 67.07 | 1,299,558 |
| 2022-01-03 | De Backer Marianne (Director) | Sale | 4,500 | 65.17 | 293,265 |
| 2022-01-03 | Waddill William D. (Director) | Sale | 4,500 | 65.16 | 293,233 |
| 2022-01-03 | Perry Michael S (Director) | Sale | 4,500 | 65.22 | 293,503 |
| 2022-01-03 | Olukotun Adeoye Y (Director) | Sale | 4,050 | 65.18 | 263,991 |
| 2021-12-31 | O'brien Patrick (General Counsel) | Option Ex | 28,000 | 6.15 | 172,200 |
| 2021-12-28 | Ferrari Mauro (Director) | Sale | 3,400 | 66.82 | 227,187 |
| 2021-12-28 | Given Douglas B (Director) | Buy | 655 | 66.37 | 43,472 |
| 2021-12-23 | Anzalone Christopher Richard (Chief Executive Officer) | Option Ex | 11,806 | 5.19 | 61,273 |
| 2021-12-15 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 60,000 | 68.28 | 4,096,560 |
| 2021-11-19 | San Martin Javier (Chief Medical Officer) | Sale | 19,500 | 70.00 | 1,365,058 |
| 2021-10-22 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 50,000 | 65.83 | 3,291,500 |
| 2021-10-20 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 15,000 | 66.23 | 993,450 |
| 2021-09-13 | Olukotun Adeoye Y (Director) | Sale | 5,000 | 63.76 | 318,800 |
| 2021-09-09 | Given Douglas B (Director) | Sale | 5,000 | 65.24 | 326,200 |
| 2021-06-24 | De Backer Marianne (Director) | Sale | 5,000 | 89.85 | 449,250 |
| 2021-06-22 | Hassard James (Chief Commercial Officer) | Sale | 3,625 | 89.22 | 323,422 |
| 2021-02-22 | Given Douglas B (Director) | Sale | 1,125 | 88.73 | 99,821 |
| 2021-02-08 | O'brien Patrick (General Counsel) | Sale | 90,000 | 88.33 | 7,950,149 |
| 2021-02-08 | O'brien Patrick (General Counsel) | Option Ex | 90,000 | 5.22 | 469,800 |
| 2021-01-15 | Given Douglas B (Director) | Sale | 3,000 | 83.28 | 249,840 |
| 2021-01-14 | Hamilton James C (Other) | Sale | 10,000 | 81.39 | 813,950 |
| 2021-01-12 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 1,441 | 81.00 | 116,721 |
| 2021-01-11 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 11,597 | 81.02 | 939,588 |
| 2021-01-07 | Hassard James (Chief Commercial Officer) | Sale | 15,625 | 75.00 | 1,171,875 |
| 2021-01-06 | Hamilton James C (Other) | Sale | 19,375 | 71.87 | 1,392,481 |
| 2021-01-06 | O'brien Patrick (General Counsel) | Sale | 25,000 | 71.91 | 1,797,675 |
| 2021-01-06 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 30,625 | 71.72 | 2,196,333 |
| 2021-01-05 | Hamilton James C (Other) | Sale | 19,375 | 72.53 | 1,405,268 |
| 2021-01-04 | Waddill William D. (Director) | Sale | 3,750 | 76.08 | 285,300 |
| 2021-01-04 | Perry Michael S (Director) | Sale | 4,000 | 76.09 | 304,360 |
| 2021-01-04 | Given Douglas B (Director) | Sale | 4,000 | 76.08 | 304,320 |
| 2020-12-18 | Anzalone Christopher Richard (Chief Executive Officer) | Option Ex | 40,510 | 5.45 | 220,779 |
| 2020-12-17 | Given Douglas B (Director) | Sale | 9,575 | 79.44 | 760,685 |
| 2020-12-10 | Waddill William D. (Director) | Sale | 3,000 | 70.80 | 212,400 |
| 2020-12-09 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 38,676 | 69.89 | 2,702,988 |
| 2020-12-09 | Anzalone Christopher Richard (Chief Executive Officer) | Option Ex | 38,676 | 2.01 | 77,738 |
| 2020-12-08 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 16,324 | 67.97 | 1,109,542 |
| 2020-12-08 | Anzalone Christopher Richard (Chief Executive Officer) | Option Ex | 16,324 | 2.01 | 32,811 |
| 2020-11-20 | Bradshaw Curt (Chief Scientific Officer) | Sale | 15,625 | 68.73 | 1,073,906 |
| 2020-11-19 | Bradshaw Curt (Chief Scientific Officer) | Sale | 15,625 | 69.39 | 1,084,218 |
| 2020-11-19 | San Martin Javier (Chief Medical Officer) | Sale | 19,500 | 69.39 | 1,353,105 |
| 2020-11-09 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 43,505 | 69.45 | 3,021,422 |
| 2020-11-09 | Myszkowski Kenneth Allen (Chief Financial Officer) | Option Ex | 43,505 | 14.54 | 632,562 |
| 2020-10-23 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 100,000 | 58.37 | 5,836,500 |
| 2020-10-20 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 29,166 | 54.04 | 1,576,130 |
| 2020-10-20 | Myszkowski Kenneth Allen (Chief Financial Officer) | Option Ex | 29,166 | 6.15 | 179,370 |
| 2020-10-09 | Ferrari Mauro (Director) | Sale | 10,000 | 48.00 | 480,000 |
| 2020-10-08 | De Backer Marianne (Director) | Buy | 1,000 | 50.47 | 50,465 |
| 2020-08-13 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 50,000 | 41.35 | 2,067,500 |
| 2020-08-13 | Anzalone Christopher Richard (Chief Executive Officer) | Option Ex | 50,000 | 9.90 | 495,000 |
| 2020-06-25 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 100,000 | 39.18 | 3,918,000 |
| 2020-06-15 | De Backer Marianne (Director) | Buy | 500 | 31.33 | 15,665 |
| 2020-05-14 | Perry Michael S (Director) | Option Ex | 77,000 | 3.49 | 268,961 |
| 2020-05-12 | Perry Michael S (Director) | Sale | 36,000 | 36.06 | 1,298,340 |
| 2020-05-11 | Waddill William D. (Director) | Sale | 26,000 | 36.54 | 950,040 |
| 2020-04-28 | Given Bruce D (Chief Operating Officer) | Sale | 5,101 | 40.00 | 204,040 |
| 2020-04-28 | Given Bruce D (Chief Operating Officer) | Option Ex | 4,197 | 7.49 | 31,418 |
| 2020-04-27 | Given Bruce D (Chief Operating Officer) | Sale | 300 | 40.00 | 12,000 |
| 2020-04-27 | Given Bruce D (Chief Operating Officer) | Option Ex | 200 | 5.19 | 1,038 |
| 2020-04-20 | Given Bruce D (Chief Operating Officer) | Sale | 23,515 | 40.00 | 940,600 |
| 2020-04-20 | Given Bruce D (Chief Operating Officer) | Option Ex | 16,256 | 7.42 | 120,619 |
| 2020-04-15 | De Backer Marianne (Director) | Buy | 500 | 35.40 | 17,700 |
| 2020-04-14 | Given Douglas B (Director) | Sale | 25,000 | 36.89 | 922,250 |
| 2020-03-16 | De Backer Marianne (Director) | Buy | 500 | 23.94 | 11,970 |
| 2020-03-12 | De Backer Marianne (Director) | Buy | 500 | 24.80 | 12,400 |
| 2020-03-11 | De Backer Marianne (Director) | Buy | 500 | 28.60 | 14,300 |
| 2020-02-28 | De Backer Marianne (Director) | Buy | 500 | 34.39 | 17,195 |
| 2020-02-27 | De Backer Marianne (Director) | Buy | 500 | 35.07 | 17,535 |
| 2020-01-21 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 40,313 | 49.55 | 1,997,428 |
| 2020-01-21 | Myszkowski Kenneth Allen (Chief Financial Officer) | Option Ex | 33,351 | 5.19 | 173,091 |
| 2020-01-13 | De Backer Marianne (Director) | Buy | 500 | 54.95 | 27,475 |
| 2020-01-06 | O'brien Patrick (General Counsel) | Sale | 14,625 | 60.35 | 882,662 |
| 2020-01-06 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 20,000 | 60.32 | 1,206,340 |
| 2020-01-06 | Given Bruce D (Chief Operating Officer) | Sale | 35,613 | 60.31 | 2,147,820 |
| 2019-12-24 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 83,333 | 63.50 | 5,291,645 |
| 2019-12-13 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 83,333 | 66.95 | 5,579,144 |
| 2019-12-12 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 100,000 | 68.01 | 6,801,200 |
| 2019-12-03 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 12,033 | 61.37 | 738,405 |
| 2019-12-02 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 37,967 | 69.72 | 2,646,907 |
| 2019-11-05 | Myszkowski Kenneth Allen (Chief Financial Officer) | Option Ex | 12,649 | 5.19 | 65,648 |
| 2019-11-01 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 37,884 | 40.88 | 1,548,887 |
| 2019-11-01 | Myszkowski Kenneth Allen (Chief Financial Officer) | Option Ex | 37,884 | 7.75 | 293,601 |
| 2019-10-10 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 56,325 | 31.83 | 1,792,824 |
| 2019-10-10 | Anzalone Christopher Richard (Chief Executive Officer) | Option Ex | 56,325 | 5.20 | 292,890 |
| 2019-09-25 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 20,000 | 28.25 | 565,000 |
| 2019-09-24 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 66,645 | 28.52 | 1,900,715 |
| 2019-09-24 | Anzalone Christopher Richard (Chief Executive Officer) | Option Ex | 66,645 | 5.10 | 339,889 |
| 2019-09-23 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 41,755 | 29.04 | 1,212,565 |
| 2019-09-23 | Anzalone Christopher Richard (Chief Executive Officer) | Option Ex | 41,755 | 5.10 | 212,950 |
| 2019-09-20 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 4,250 | 29.00 | 123,250 |
| 2019-09-20 | Anzalone Christopher Richard (Chief Executive Officer) | Option Ex | 4,250 | 5.10 | 21,675 |
| 2019-09-11 | Perry Michael S (Director) | Sale | 85,000 | 30.00 | 2,550,000 |
| 2019-09-09 | Perry Michael S (Director) | Sale | 100,000 | 28.90 | 2,890,000 |
| 2019-06-26 | Ferrari Mauro (Director) | Sale | 17,756 | 27.61 | 490,243 |
| 2019-05-31 | Myszkowski Kenneth Allen (Chief Financial Officer) | Option Ex | 35,000 | 4.89 | 171,324 |
| 2019-05-28 | O'brien Patrick (General Counsel) | Sale | 30,000 | 24.88 | 746,400 |
| 2019-05-24 | Anzalone Christopher Richard (Chief Executive Officer) | Option Ex | 49,448 | 2.31 | 114,472 |
| 2019-05-21 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 27,071 | 22.00 | 595,562 |
| 2019-04-03 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 50,000 | 19.30 | 965,000 |
| 2019-03-01 | Given Bruce D (Chief Operating Officer) | Sale | 42,500 | 19.99 | 849,574 |
| 2019-03-01 | Given Bruce D (Chief Operating Officer) | Option Ex | 42,500 | 2.01 | 85,424 |
| 2019-02-26 | Given Douglas B (Director) | Sale | 195,000 | 19.25 | 3,753,750 |
| 2019-02-26 | Given Douglas B (Director) | Option Ex | 195,000 | 3.69 | 719,160 |
| 2019-02-25 | Given Bruce D (Chief Operating Officer) | Sale | 42,500 | 18.98 | 806,650 |
| 2019-02-25 | Given Bruce D (Chief Operating Officer) | Option Ex | 42,500 | 2.01 | 85,424 |
| 2019-02-22 | Given Douglas B (Director) | Sale | 9,000 | 18.05 | 162,450 |
| 2019-02-19 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 8,000 | 18.00 | 144,000 |
| 2019-02-19 | Myszkowski Kenneth Allen (Chief Financial Officer) | Option Ex | 8,000 | 5.20 | 41,600 |
| 2019-02-19 | Given Bruce D (Chief Operating Officer) | Sale | 42,500 | 17.98 | 764,150 |
| 2019-02-19 | Given Bruce D (Chief Operating Officer) | Option Ex | 42,500 | 2.01 | 85,424 |
| 2019-02-15 | Given Bruce D (Chief Operating Officer) | Sale | 26,250 | 17.67 | 463,837 |
| 2019-02-12 | Given Bruce D (Chief Operating Officer) | Sale | 42,500 | 17.06 | 725,050 |
| 2019-02-12 | Given Bruce D (Chief Operating Officer) | Option Ex | 42,500 | 2.01 | 85,424 |
| 2019-02-11 | Given Bruce D (Chief Operating Officer) | Sale | 154,167 | 16.07 | 2,477,463 |
| 2019-02-11 | Given Bruce D (Chief Operating Officer) | Option Ex | 11,667 | 2.62 | 30,567 |
| 2019-02-08 | Given Bruce D (Chief Operating Officer) | Sale | 46,167 | 15.34 | 708,201 |
| 2019-02-08 | Given Bruce D (Chief Operating Officer) | Option Ex | 11,667 | 2.62 | 30,567 |
| 2019-02-05 | Given Bruce D (Chief Operating Officer) | Sale | 22,500 | 14.48 | 325,800 |
| 2019-02-01 | Given Bruce D (Chief Operating Officer) | Sale | 28,500 | 13.85 | 394,725 |
| 2019-01-23 | Given Bruce D (Chief Operating Officer) | Sale | 17,500 | 13.15 | 230,125 |
| 2019-01-22 | Given Bruce D (Chief Operating Officer) | Sale | 152,000 | 13.59 | 2,065,680 |
| 2019-01-22 | Given Douglas B (Director) | Sale | 3,000 | 13.58 | 40,740 |
| 2019-01-18 | O'brien Patrick (General Counsel) | Sale | 72,000 | 14.43 | 1,038,960 |
| 2019-01-17 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 81,875 | 14.55 | 1,191,281 |
| 2019-01-14 | Li Zhen (Snr. VP, Chem and Non-Clin Dev) | Sale | 40,500 | 14.34 | 580,770 |
| 2019-01-14 | Given Bruce D (Chief Operating Officer) | Sale | 42,666 | 14.40 | 614,390 |
| 2019-01-14 | Given Bruce D (Chief Operating Officer) | Option Ex | 12,666 | 4.41 | 55,857 |
| 2019-01-11 | Waddill William D. (Director) | Sale | 8,500 | 14.77 | 125,545 |
| 2019-01-02 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 8,333 | 11.98 | 99,829 |
| 2019-01-02 | Given Bruce D (Chief Operating Officer) | Sale | 20,000 | 11.98 | 239,600 |
| 2018-12-27 | Given Douglas B (Director) | Sale | 3,000 | 12.00 | 36,000 |
| 2018-12-19 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 90,000 | 13.92 | 1,252,800 |
| 2018-12-12 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 90,000 | 14.07 | 1,266,300 |
| 2018-11-23 | Given Douglas B (Director) | Sale | 3,000 | 12.74 | 38,220 |
| 2018-11-09 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 81,500 | 14.65 | 1,193,975 |
| 2018-10-19 | Leone Peter Brian (VP, Strategic Bus. Initiatives) | Sale | 131,137 | 13.49 | 1,769,038 |
| 2018-10-19 | Leone Peter Brian (VP, Strategic Bus. Initiatives) | Option Ex | 131,137 | 5.56 | 729,515 |
| 2018-09-06 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 45,000 | 19.50 | 877,725 |
| 2018-09-06 | Myszkowski Kenneth Allen (Chief Financial Officer) | Option Ex | 45,000 | 3.69 | 165,825 |
| 2018-09-04 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 64,834 | 14.45 | 936,851 |
| 2018-08-31 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 100,000 | 14.45 | 1,445,000 |
| 2018-06-19 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 20,000 | 14.01 | 280,200 |
| 2018-06-19 | Myszkowski Kenneth Allen (Chief Financial Officer) | Option Ex | 20,000 | 2.01 | 40,199 |
| 2018-05-31 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 12,600 | 11.00 | 138,600 |
| 2018-05-31 | Myszkowski Kenneth Allen (Chief Financial Officer) | Option Ex | 12,600 | 2.01 | 25,325 |
| 2018-05-30 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 1,400 | 11.00 | 15,400 |
| 2018-05-30 | Myszkowski Kenneth Allen (Chief Financial Officer) | Option Ex | 1,400 | 2.01 | 2,813 |
| 2018-04-24 | Given Douglas B (Director) | Sale | 25,000 | 6.63 | 165,750 |
| 2018-03-27 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 20,000 | 8.00 | 160,000 |
| 2018-03-27 | Myszkowski Kenneth Allen (Chief Financial Officer) | Option Ex | 20,000 | 2.01 | 40,199 |
| 2018-03-16 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 26,000 | 7.40 | 192,400 |
| 2018-03-15 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 100,000 | 7.41 | 741,000 |
| 2018-03-14 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 100,000 | 7.44 | 744,000 |
| 2018-03-13 | Anzalone Christopher Richard (Chief Executive Officer) | Sale | 100,000 | 7.43 | 743,000 |
| 2018-03-05 | Given Bruce D (Chief Operating Officer) | Sale | 20,000 | 6.73 | 134,600 |
| 2018-01-01 | Given Bruce D (Chief Operating Officer) | Sale | 20,000 | 3.69 | 73,800 |
| 2016-10-14 | Given Douglas B (Director) | Sale | 12,000 | 6.72 | 80,640 |
| 2016-08-23 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 6,900 | 8.00 | 55,200 |
| 2016-08-23 | Myszkowski Kenneth Allen (Chief Financial Officer) | Option Ex | 6,900 | 2.01 | 13,868 |
| 2016-08-22 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 13,100 | 8.00 | 104,800 |
| 2016-08-22 | Myszkowski Kenneth Allen (Chief Financial Officer) | Option Ex | 13,100 | 2.01 | 26,330 |
| 2016-06-30 | Anzalone Christopher Richard (Chief Executive Officer) | Option Ex | 15,772 | 5.09 | 80,279 |
| 2015-12-30 | Myszkowski Kenneth Allen (Chief Financial Officer) | Sale | 23,347 | 6.13 | 143,117 |
| 2015-01-05 | Lewis David L. (Chief Scientific Officer) | Sale | 15,000 | 8.01 | 120,105 |
| 2015-01-05 | Lewis David L. (Chief Scientific Officer) | Option Ex | 15,000 | 2.01 | 30,149 |
| 2013-10-28 | Ferrari Mauro (Director) | Buy | 400 | 7.62 | 3,047 |
| 2013-10-09 | Ferrari Mauro (Director) | Buy | 1,900 | 6.19 | 11,761 |
Insider trading activities including stock purchases, stock sales, and option exercises
of ARWR listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Arrowhead Pharmaceuticals, Inc. (symbol ARWR,
CIK number 879407) see
the Securities and Exchange Commission (SEC) website.